Results 71 to 80 of about 11,256 (207)

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps

, 2021
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, preclinical and clinical research with PARPi has revealed multiple
Annunziato, Stefano, Manolika, Eleni-Maria, Cong, Ke, Rottenberg, Sven, Gogola, Ewa, Beijersbergen, Roderick, Bartek, Jiri, Bhin, Jinhyuk, Galanos, Panagiotis, Andújar-Sánchez, Miguel, Jonkers, Jos, Tripathi, Vivek, Chakrabarty, Synjiban, van der Heijden, Ingrid, Smith, Graeme C. M., Bartkova, Jirina, Paes Dias, Mariana, Cantor, Sharon, Chaudhuri, Arnab Ray, Lieftink, Cor, van de Ven, Marieke   +20 more
core   +1 more source

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

The Prostate, EarlyView.
ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi).
Lorena Incorvaia, Veronica Mollica, Ondřej Fiala, Kazutoshi Fujita, Yüksel Ürün, Bohuslav Melichar, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Umberto Basso, Maria T. Bourlon, Emmanuel Seront, Ugo De Giorgi, Maria José Juan Fita, Pasquale Rescigno, Tarek Taha, Fernando C. Maluf, Alexandr Poprach, Simona De Summa, Tomas Buchler, Luca Galli, Jindrich Kopecky, Gaetano Aurilio, Jakub Kucharz, Carlo Messina, Gabriel Berlingieri Polho, Sarah Scagliarini, Francesco Grillone, Diogo Assed Bastos, Luigi Formisano, Gian Paolo Spinelli, Alessandra Mosca, Alessandro Rizzo, Aristotelis Bamias, Fernando Sabino Marques Monteiro, Andrey Soares, Francesco Massari, Andrew J. Armstrong, Matteo Santoni   +37 more
wiley   +1 more source

Resistance to PARP-inhibitors in Cancer Therapy

Frontiers in Pharmacology, 2013
The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers.
Alicia eMontoni, Mihaela eRobu, Emilie ePouliot, Girish M. Shah   +3 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Selective autophagy pathways in ageing and neurodegeneration: Emerging roles for mitophagy and nucleophagy

The FEBS Journal, EarlyView.
As we age, cells gradually accumulate damage, which can contribute to disease and neurodegeneration. This review explores how two cellular recycling processes, mitophagy and nucleophagy, remove damaged mitochondria and nuclear material, respectively, to maintain cell health and long‐term neuronal homeostasis.
Maria Markaki, Nektarios Tavernarakis
wiley   +1 more source

PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer

Journal of Experimental & Clinical Cancer Research
Background Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in prostate cancer (PCa). Although branched-chain amino acid (BCAA) metabolism is implicated in cancer biology, its specific role in PARPi resistance ...
Wangli Mei, Hang Zhou, Weiyi Li, Yongqiang Liu, Chaozhi Tang, Mengyu Wei, Zhen Zhou, Bowen Ye, Hanwen Niu, Weitian Wang, Kaiqi Yang, Yue Zhang, Liqun Huang, Yang Yu, Xiaofei Wen, Lin Ye   +15 more
doaj   +1 more source

Mechanism of PARP inhibitor resistance and potential overcoming strategies

Genes and Diseases
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process.
Xiaoyu Fu, Ping Li, Qi Zhou, Ruyuan He, Guannan Wang, Shiya Zhu, Amir Bagheri, Gary Kupfer, Huadong Pei, Juanjuan Li   +9 more
doaj   +1 more source

Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications

International Journal of Cancer, Volume 160, Issue 1, Page 7-23, 1 January 2027.
ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing, Chang Zhou, Yi Tang, Shuhui Xu, Shasha Zhou, Weiai Liu, Huiping Liu   +6 more
wiley   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Advanced Science
Mutations in isocitrate dehydrogenase (IDH) genes sensitize gliomas to PARP inhibition (PARPi) by inducing epigenetic reprogramming of DNA damage repair circuits. However, tumors treated with PARPi eventually relapse despite initial responsiveness.
Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu, Jason T. Huse, Bo Chen, Timothy A. Chan, Zengxin Qi, Zhao Zhang, Xiuping Liu, Yuxiang Wang   +16 more
doaj   +1 more source

Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS–STING–STAT3 survival axis

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Abstract Background Ovarian cancer (OC) remains the most lethal gynaecological malignancy, and acquired resistance to PARP inhibitors such as olaparib represents a major clinical challenge. Although dysregulation of iron metabolism has been implicated in tumorigenesis, the specific role of the iron exporter SLC40A1 (ferroportin, FPN) in mediating ...
Jiagui Song, Zhengyang Guo, Decao Yang, Ping Yu, Yinjia Li, Zhuhui Yuan, Xiaojuan Ma, Xianlong Li, Hongyan Guo, Lixiang Xue, Tong Liu   +10 more
wiley   +1 more source